Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 12/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710480 | 0.98 | P2RX3 (0.41) | P2RX3S1PR1P2RX2S1PR3S1PR5 | |
| SCHEMBL6710485 | 0.97 | P2RX3 (0.41) | P2RX3S1PR1P2RX2S1PR3S1PR5 | |
| SCHEMBL6710422 | 0.96 | P2RX3 (0.46) | P2RX3S1PR1P2RX2S1PR3S1PR5 | |
| SCHEMBL6712268 | 0.91 | PDE11A (0.43) | — | |
| SCHEMBL6712329 | 0.91 | PDE5A (0.42) | — | |
| SCHEMBL6763429 | 0.89 | FFAR1 (0.42) | — | |
| SCHEMBL6708873 | 0.89 | PDE11A (0.42) | — | |
| SCHEMBL6709028 | 0.88 | PDE5A (0.42) | P2RX3 | |
| SCHEMBL6710476 | 0.88 | PDE11A (0.42) | — | |
| SCHEMBL6707574 | 0.88 | PDE5A (0.42) | P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777419-B1 | EXHIBIT PHOSPHODIESTERASE V INHIBITION AND CAN BE EMPLOYED FOR THE TREATMENT OF DISORDERS OF THE CARDIOVASCULAR SYSTEM OR ERECTILE DYSFUNCTION | MERCK PATENT GMBH (DE) | 2004-08-17 | — | — | US | disclosed |
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | MERCK PATENT GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| US-20040063730-A1 | Pharmacuetical formulation comprising puyrazolo[4,-3-d]pyrimidines and antithrombotics, calcium antagonists, or prostaglandins or prostaglandin derivatives | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| US-20040023991-A1 | Use of pyrazolo[4,3-d]pyrimidines | MERCK PATENT GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| US-20040023990-A1 | Use of pyrazolo[4,3-d]pyrimidines | MERCK PATENT GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| EP-1357915-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GmbH (DE) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002062343-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | PTGIS, DPYD, PTGIR | P2RX3 54/4885S1PR1 1727/4885P2RX2 108/4885 |
| US-20040023990-A1 | Use of pyrazolo[4,3-d]pyrimidines | P2RX3, HRH2, HRH4 | P2RX3 1/4885S1PR1 65/4885P2RX2 8/4885 |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | EDNRA, EDNRB, PTGIR | P2RX3 84/4885S1PR1 325/4885P2RX2 171/4885 |
| US-20040023991-A1 | Use of pyrazolo[4,3-d]pyrimidines | DPYD, TYMP, PNPO | P2RX3 14/4885S1PR1 959/4885P2RX2 46/4885 |
| US-20040063730-A1 | Pharmacuetical formulation comprising puyrazolo[4,-3-d]pyrimidines and antithrombotics, calcium antagonists, or prostaglandins or prostaglandin derivatives | PTGIS, PTGIR, PTGER1 | P2RX3 21/4885S1PR1 218/4885P2RX2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.